Few peptides have generated as much scientific interest over the past three decades as BPC-157. Known formally as Body Protection Compound-157, this synthetic pentadecapeptide derived from human gastric juice has accumulated one of the largest bodies of preclinical research of any compound currently under active investigation. With over 500 published studies spanning tissue repair, gastrointestinal research, vascular biology, neuroscience, and musculoskeletal healing, BPC-157 sits at the centre of regenerative peptide science in 2026. This post provides a comprehensive educational overview of what BPC-157 is, how it works, and what the current research landscape tells us. All information is provided strictly for educational and research purposes only.
What Is BPC-157?
BPC-157, known as the Body Protection Compound, is a pentadecapeptide isolated from human gastric juice that has demonstrated pleiotropic beneficial effects in various preclinical models mimicking medical conditions such as tissue injury, inflammatory bowel disease, and CNS disorders. Unlike many other compounds, BPC-157 has a desirable safety profile since only a few side effects have been reported following its administration. ClinicalTrials.gov
The compound is a 15 amino acid sequence — hence pentadecapeptide — and is a partial sequence of a naturally occurring protein found in gastric juice. Its endogenous origin makes it a particularly interesting research subject as it mirrors biological sequences the body already produces, raising questions about its role in natural tissue protection and repair mechanisms.
Origins and Discovery
BPC-157 research has been led primarily by Croatian researcher Professor Predrag Sikiric and his team at the University of Zagreb School of Medicine, who have published extensively on the compound since the early 1990s. The compound was identified as a stable fragment of the body protection compound found in gastric juice and demonstrated remarkable stability compared to the full protein sequence — maintaining biological activity even under conditions that would degrade larger proteins.
Key Mechanisms of Action
BPC-157 operates through several well-documented molecular pathways that collectively explain its broad research profile across multiple tissue types and organ systems.
BPC-157 enhances growth hormone receptor expression and modulates several pathways involved in cell growth and angiogenesis while reducing inflammatory cytokines. BioSpace
Its primary mechanisms include activation of the VEGFR2 angiogenesis signalling pathway — which drives the formation of new blood vessels essential for tissue repair — stabilisation of nitric oxide production, reduction of oxidative stress markers, enhancement of fibroblast activity, and modulation of the extracellular matrix. These combined effects give BPC-157 a multi-vector approach to tissue repair that researchers have found particularly valuable in complex injury models.
Musculoskeletal Research
The majority of BPC-157's research profile focuses on musculoskeletal applications — tendon, ligament, muscle, and bone repair. BPC-157 is a naturally occurring gastric peptide that promotes mucosal integrity and homeostasis. Preclinical studies show its potential for promoting healing in musculoskeletal injuries such as fractures, tendon ruptures, ligament tears, and muscle injuries. Eli Lilly and Company
A systematic review published in 2025 examined 36 studies published from 1993 to 2024. The findings showed that BPC-157 helps promote healing by boosting growth factors and reducing inflammation. It has improved outcomes in muscle, tendon, ligament, and bone injury models in animals. PubMed Central
Human Research
While the vast majority of BPC-157 research has been conducted in preclinical animal models, human research is beginning to emerge. In one human study, 7 out of 12 people with chronic knee pain felt relief for over six months after receiving one BPC-157 knee injection. PubMed Central
Most recently, a pilot study involving two healthy adults who received intravenous BPC-157 infusions up to 20mg was conducted. The study represents an early but important step toward establishing a human safety and pharmacokinetics profile for the compound. PharmExec
Gastrointestinal Research
BPC-157's origins in gastric juice research have made the gastrointestinal tract one of the most extensively studied areas of its research profile. Preclinical studies show its cytoprotective and pro-healing effects throughout the gastrointestinal tract, including healing GI ulcers, anastomotic sites, various GI fistulas, as well as in models of inflammatory bowel disease. BioSpace
The compound's ability to protect mucosal integrity and accelerate repair of gastrointestinal tissue has made it particularly interesting to researchers studying conditions where the intestinal lining is compromised.
Pharmacokinetics
After a single intravenous administration, the elimination half-life of BPC-157 was less than 30 minutes, and BPC-157 showed linear pharmacokinetic characteristics in rats and beagle dogs at all doses. The mean absolute bioavailability of BPC-157 following intramuscular injection was approximately 14 to 19 percent in rats and 45 to 51 percent in beagle dogs. The main excretory pathways involved urine and bile. Retatrutide
Vascular and Nitric Oxide Research
One of the most consistently documented mechanisms in BPC-157 research is its interaction with the nitric oxide system — the biological pathway that regulates vascular tone, blood flow, and endothelial function. Researchers have documented BPC-157's ability to stabilise nitric oxide production in conditions where it is dysregulated, which has implications for vascular repair research and conditions involving compromised blood flow to tissues.
This interaction with the nitric oxide pathway also partially explains BPC-157's documented effects on angiogenesis — the formation of new blood vessels — which is a critical process in wound healing and tissue regeneration across virtually every organ system.
Neurological Research
Beyond its musculoskeletal and gastrointestinal research profile, BPC-157 has been studied in neurological contexts. BPC-157 has demonstrated pleiotropic beneficial effects in preclinical models mimicking CNS disorders. ClinicalTrials.gov
Research has explored its effects on dopaminergic and serotonergic systems, its potential neuroprotective properties, and its interaction with the gut-brain axis — an area of growing scientific interest given the compound's origin in the gastrointestinal system and its documented effects on both gut and brain tissue in preclinical models.
Safety Profile
Unlike many other compounds, BPC-157 has a desirable safety profile since only a few side effects have been reported following its administration. ClinicalTrials.gov
The 2025 systematic review across 36 studies noted the absence of significant adverse effects in preclinical models, and the pilot human intravenous study reported the compound was well-tolerated. However the authors of multiple reviews consistently emphasise that the absence of large-scale randomised controlled trials in humans means the full safety profile for human use remains incompletely characterised.
Regulatory Status
BPC-157 was temporarily banned by the World Anti-Doping Agency in 2022 but is not currently listed as banned by WADA. However it has not been approved for use in standard medicine by the FDA and other global regulatory authorities due to the absence of sufficient and comprehensive clinical studies confirming its benefits in humans. ClinicalTrials.gov
Research Grade BPC-157 from BioSupply UK
BioSupply UK supplies BPC-157 as a research grade compound at 99%+ purity, independently third party lab tested and HPLC verified. Available in 5mg and 10mg vials with Certificates of Analysis available on request. Also available as part of our Wolverine Stack alongside TB-500 and our Glow Stack combined with TB-500 and GHK-CU. Strictly for laboratory and in-vitro scientific research only.
This content is provided for educational and research purposes only and does not constitute medical advice. BPC-157 is not approved for human therapeutic use and should not be used outside of a controlled laboratory research setting.